Mar 8, 2023

Estrella Biopharma Announces FDA Clearance of IND Application for Phase I/II Clinical Trial (Starlight-1) of EB103, a CD19-Targeted ARTEMIS® T Cell Therapy, to Patients with B-Cell Lymphomas

Nov 14, 2022

Imugene’s onCARlytics combination with Estrella’s CD19-Redirected ARTEMIS® T Cells presented at SITC Annual Meeting

Oct 3, 2022

Estrella Biopharma, Inc., a biopharmaceutical company to Become a Publicly Traded Company Via Merger with TradeUP Acquisition Corp.